A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

Objective To assess dosing, preliminary safety, and efficacy of canakinumab, a fully human anti–interleukin‐1β (anti–IL‐1β) antibody, in children with systemic juvenile idiopathic arthritis (JIA) and active systemic features. Methods In this phase II, multicenter, open‐label, dosage‐escalation study...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2012-02, Vol.64 (2), p.557-567
Hauptverfasser:	Ruperto, Nicolino, Quartier, Pierre, Wulffraat, Nico, Woo, Patricia, Ravelli, Angelo, Mouy, Richard, Bader-Meunier, Brigitte, Vastert, Sebastiaan J., Noseda, Emanuele, D'Ambrosio, Daniele, Lecot, Jean, Chakraborty, Abhijit, Martini, Alberto, Chioato, Andrea
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Juvenile - drug therapy Biological and medical sciences Child Child, Preschool Confidence intervals Diseases of the osteoarticular system Dose-Response Relationship, Drug Female Humans Immunomodulators Inflammatory joint diseases Interleukin-1beta - antagonists & inhibitors Male Medical sciences Pediatrics Pharmacology. Drug treatments Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!